Publicacións en colaboración con investigadores/as de University of Texas MD Anderson Cancer Center (77)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

2023

  1. Association between duration of smoking abstinence before non-small-cell lung cancer diagnosis and survival: a retrospective, pooled analysis of cohort studies

    The Lancet. Public health, Vol. 8, Núm. 9, pp. e691-e700

  2. Characterizing prostate cancer risk through multi-ancestry genome-wide discovery of 187 novel risk variants

    Nature Genetics, Vol. 55, Núm. 12, pp. 2065-2074

  3. ENIGMA CHEK2gether Project: A Comprehensive Study Identifies Functionally Impaired CHEK2 Germline Missense Variants Associated with Increased Breast Cancer Risk

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 16, pp. 3037-3050

  4. Evaluating approaches for constructing polygenic risk scores for prostate cancer in men of African and European ancestry

    American Journal of Human Genetics, Vol. 110, Núm. 7, pp. 1200-1206

  5. Genetically proxied glucose-lowering drug target perturbation and risk of cancer: a Mendelian randomisation analysis

    Diabetologia, Vol. 66, Núm. 8, pp. 1481-1500

  6. Genome-wide Association Study of Bladder Cancer Reveals New Biological and Translational Insights

    European Urology, Vol. 84, Núm. 1, pp. 127-137

  7. PREDICT validity for prognosis of breast cancer patients with pathogenic BRCA1/2 variants

    npj Breast Cancer, Vol. 9, Núm. 1

2022

  1. Accounting for EGFR Mutations in Epidemiologic Analyses of Non–Small Cell Lung Cancers: Examples Based on the International Lung Cancer Consortium Data

    Cancer Epidemiology Biomarkers and Prevention, Vol. 31, Núm. 3, pp. 679-687

  2. Copy number variants as modifiers of breast cancer risk for BRCA1/BRCA2 pathogenic variant carriers

    Communications biology, Vol. 5, Núm. 1, pp. 1061

  3. Erratum: Correction: Polygenic risk modeling for prediction of epithelial ovarian cancer risk (European journal of human genetics : EJHG (2022) 30 3 (349-362))

    European journal of human genetics : EJHG

  4. First international workshop of the ATM and cancer risk group (4-5 December 2019)

    Familial Cancer, Vol. 21, Núm. 2, pp. 211-227

  5. Intratumor genetic heterogeneity and clonal evolution to decode endometrial cancer progression

    Oncogene, Vol. 41, Núm. 13, pp. 1835-1850

  6. Macrophages direct cancer cells through a LOXL2-mediated metastatic cascade in pancreatic ductal adenocarcinoma

    Gut, Vol. 72, Núm. 2, pp. 345-359

  7. Polygenic risk modeling for prediction of epithelial ovarian cancer risk

    European journal of human genetics : EJHG, Vol. 30, Núm. 3, pp. 349-362

  8. Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score

    Prostate cancer and prostatic diseases, Vol. 25, Núm. 4, pp. 755-761

  9. Severe de novo pustular psoriasiform immune-related adverse event associated with nivolumab treatment for metastatic esophageal adenocarcinoma

    Journal of Cutaneous Pathology, Vol. 49, Núm. 5, pp. 472-481

  10. Uterine Inflammatory Myofibroblastic Neoplasms with Aggressive Behavior, including an Epithelioid Inflammatory Myofibroblastic Sarcoma: A Clinicopathologic Study of 9 Cases

    American Journal of Surgical Pathology, Vol. 46, Núm. 1, pp. 105-117

2021

  1. A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers

    Nature Communications, Vol. 12, Núm. 1